Novartis’ Cosentyx secures FDA approval for hidradenitis suppurativa
The FDA approval for the IL-17A inhibitor was based on the findings of a Phase 3 programme, which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Nov 23
The FDA approval for the IL-17A inhibitor was based on the findings of a Phase 3 programme, which…
01 Nov 23
NVX-CoV2601 is an updated iteration of Novavax's initial COVID-19 vaccine NVX-CoV2373 and is tailored specifically to target the…
01 Nov 23
Stelara is an approved human interleukin-12 and interleukin-23 antagonist, which was developed by Janssen Pharmaceuticals, a subsidiary of…
31 Oct 23
The breakthrough therapy designation is intended for the treatment of patients diagnosed with previously untreated, locally advanced, or…
27 Oct 23
Omvoh is an IL-23p19 antagonist, approved to treat moderate to severely active ulcerative colitis (UC) in adults, based…
27 Oct 23
The approval is based on the positive results from the phase 3 BALATON and COMINO trials in which…
25 Oct 23
The approval was based on the data from the Phase 1, multicentre study of IDH1-mutated R/R MDS patients…
24 Oct 23
The agreement with the direct purchasers will mark the conclusion of the MDL, once the settlements for the…
20 Oct 23
The European Commission has unconditionally approved the transaction, concluding that the proposed transaction would not significantly reduce competition…
17 Oct 23
In the US, Keytruda has been approved in combination with platinum-based chemotherapy as neoadjuvant treatment for resectable NSCLC…